These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25359244)

  • 1. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy.
    Mohammad RA; Bulloch MN; Chan J; Deming P; Love B; Smith L; Dong BJ; GI Liver Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy
    Pharmacotherapy; 2014 Dec; 34(12):1341-54. PubMed ID: 25359244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection - an alternative viewpoint.
    Schafer JJ
    Pharmacotherapy; 2015 Apr; 35(4):e37-8. PubMed ID: 25884535
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution.
    Gauthier TP; Moreira E; Chan C; Cabrera A; Toro M; Carrasquillo MZ; Corentin M; Sherman EM
    J Am Pharm Assoc (2003); 2016; 56(6):670-676. PubMed ID: 27667501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.
    ; Yee HS; Currie SL; Darling JM; Wright TL
    Am J Gastroenterol; 2006 Oct; 101(10):2360-78. PubMed ID: 17032203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network.
    Milfred-Laforest SK; Chow SL; Didomenico RJ; Dracup K; Ensor CR; Gattis-Stough W; Heywood JT; Lindenfeld J; Page RL; Patterson JH; Vardeny O; Massie BM
    J Card Fail; 2013 May; 19(5):354-69. PubMed ID: 23663818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; McNicholl IR
    Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus infection and the role of a pharmaceutical care program.
    Chamorro-de-Vega E; Rodríguez-González CG; Giménez-Manzorro Á; Herranz A; Sanjurjo M
    Am J Health Syst Pharm; 2020 Mar; 77(6):479-486. PubMed ID: 31811290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacy programmatic perspectives on use of direct-acting antivirals for acquired hepatitis C infection in solid organ transplant recipients.
    Crona L; Berry H; Byrns J; Campbell U
    Am J Health Syst Pharm; 2020 Jul; 77(14):1149-1152. PubMed ID: 32537658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center.
    Isho NY; Kachlic MD; Marcelo JC; Martin MT
    J Am Pharm Assoc (2003); 2017; 57(3S):S259-S264. PubMed ID: 28506379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program.
    Ajlan AA; Al-Gain R; Ahmed M; Abu-Riash T; Alquaiz M; Alkhail FA; Alashgar H; Alkhairallah T; Alkortas D; Al-Jedai A
    J Am Pharm Assoc (2003); 2021; 61(2):e159-e170. PubMed ID: 33309191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consortium recommendations for advancing pharmacists' patient care services and collaborative practice agreements.
    American Pharmacists Association Foundation and American Pharmacists Association
    J Am Pharm Assoc (2003); 2013; 53(2):e132-41. PubMed ID: 23571636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of challenging HIV case consultations provided via teleconference by the Clinician Consultation Center to the Federal Bureau of Prisons.
    Dong BJ; Williams MR; Bingham JT; Tokumoto J; Allen JD
    J Am Pharm Assoc (2003); 2017; 57(4):516-519. PubMed ID: 28610939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics.
    Naidjate SS; Zullo AR; Dapaah-Afriyie R; Hersey ML; Marshall BDL; Winkler RM; Berard-Collins C
    Am J Health Syst Pharm; 2019 May; 76(10):646-653. PubMed ID: 30873537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Heredia Benito M; García-Cabrera E; Monje García B; Tovar Pozo M; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Apr; 41(2):488-495. PubMed ID: 31028599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities.
    Geiger R; Steinert J; McElwee G; Carver J; Montanez R; Niewoehner J; Clark C; Reilley B
    J Prim Care Community Health; 2018; 9():2150132718807520. PubMed ID: 30348039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Position paper on critical care pharmacy services. Society of Critical Care Medicine and American College of Clinical Pharmacy.
    Pharmacotherapy; 2000 Nov; 20(11):1400-6. PubMed ID: 11079290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
    Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
    Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with HIV or hepatitis C by pharmacist clinicians in a patient-centered medical home.
    Ryan KL; Jakeman B; Conklin J; Pineda LJ; Deming P; Mercier RC
    Am J Health Syst Pharm; 2019 May; 76(11):821-828. PubMed ID: 31053839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.